UMIN-CTR Clinical Trial

Recruitment status Open public recruiting
Unique ID issued by UMIN UMIN000031091
Receipt No. R000035510
Official scientific title of the study The effect of DAAs therapy for patients with HCV infection on prognosis and incidence of HCC
Date of disclosure of the study information 2018/01/31
Last modified on 2018/01/31 (Ver. 1)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Official scientific title of the study The effect of
DAAs therapy for patients
with HCV infection on prognosis and
incidence of HCC
Title of the study (Brief title) Effect of DAAs on incidence of HCC and prognosis
Region
Japan

Condition
Condition Patients with HCV infection
Classification by specialty
Hepato-biliary-pancreatic medicine
Classification by malignancy Others
Genomic information YES

Objectives
Narrative objectives1 To analyze the effect of
DAAs therapy for HCV infected patients on
HCC incidence,risk maker of incidence of
HCC and prognosis
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes To investigate incidence of HCC and
prognosis after HCV eradication.
To analyze risk factor of those
Key secondary outcomes 1 HCC incidence and prognosis in HD patients with HCV infection.
To compare HCC incidence and prognosis between patient with or without IFN-therapy
2 To investigate change in ALT and AFP
3 To investigate the change in liver fibrosis and steatosis after SVR
4 To investigate the change in lipid/glucose/Fe metabolismafter SVR
5 To investigate the rate of Hospitalization due to liver disease

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria HCV infected patients who were treated and achieved SVR between 2011 and 2026
Key exclusion criteria 1) Patients with difficult-to-control heart disease
2) Other patients judged to be inappropriate to participate in the study by the primary physician
Target sample size 400

Research contact person
Name of lead principal investigator Goki Suda
Organization Graduate School of Medicine,
Hokkaido University
Division name Department of Gastroenterology and Hepatology
Address North 15, West 7, Kita-ku, Sapporo, Hokkaido
TEL 011-716-2111
Email gsudgast@pop.med.hokudai.ac.jp

Public contact
Name of contact person Goki Suda
Organization Graduate School of Medicine, Hokkaido University
Division name Department of Gastroenterology and Hepatology
Address North 15, West 7, Kita-ku, Sapporo, Hokkaido
TEL 011-716-2111
Homepage URL
Email gsudgast@pop.med.hokudai.ac.jp

Sponsor
Institute Graduate School of Medicine, Hokkaido University
Institute
Department

Funding Source
Organization Graduate School of Medicine, Hokkaido University
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2018 Year 01 Month 31 Day

Progress
Recruitment status Open public recruiting
Date of protocol fixation
2016 Year 03 Month 23 Day
Anticipated trial start date
2016 Year 05 Month 28 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Related information
URL releasing protocol
Publication of results Unpublished
URL releasing results
Results
Other related information 1) patients background
2) blood count
3) biochemical examination
4) tumor maker
5) HCV RNA, RAV
6) glucose, lipid metabolism
7) fibrosis maker
8) radiological exmamination
9) concomitant drug
10) admission due to liver disease
11) micro RNA
12) microbiota

Management information
Registered date
2018 Year 01 Month 31 Day
Last modified on
2018 Year 01 Month 31 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000035510